Chemotherapy enhances tumor vascularization via Notch signaling-mediated formation of tumor-derived endothelium in breast cancer

Biochemical Pharmacology

Volumn 118, Issue , 2016, Pages 18-30

  Zhang, Peng ^a,b   He, Dongxu ^a   Chen, Zhen ^a   Pan, Qiongxi ^a   Du, Fangfang ^a   Zang, Xian ^a   Wang, Yan ^b   Tang, Chunlei ^a   Li, Hong ^c   Lu, He ^d   Yao, Xiaoqiang ^b   Jin, Jian ^a   Ma, Xin ^a,b  

^a JIANGNAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITÉ DE ROUEN   (France)

^d INSERM   (France)

Author keywords

Breast cancer cells; Chemotherapy; Endothelial cells; Notch signaling

Indexed keywords

ANTHRACYCLINE; CD31 ANTIGEN; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; NERVE CELL ADHESION MOLECULE; NITRIC OXIDE; NOTCH4 RECEPTOR; PACLITAXEL; PROTEIN; PROTEIN DLL3; PROTEIN P53; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR 3; VIMENTIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRIDGED COMPOUND; NOTCH RECEPTOR; TAXANE; TAXOID; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE AMPLIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROVASCULATURE; MIDDLE AGED; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; GENETICS; GERMFREE ANIMAL; MCF-7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; VASCULARIZATION;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BREAST NEOPLASMS; BRIDGED-RING COMPOUNDS; DOXORUBICIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MCF-7 CELLS; MICE, NUDE; MICROVESSELS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; RECEPTORS, NOTCH; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84989884548     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.08.008     Document Type: Article

References (43)

1. [1] Folkman, J., What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990), 4–6.
2. [2] Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995), 27–31.
3. [3] Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
4. [4] Weidner, N., Semple, J.P., Welch, W.R., Folkman, J., Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991), 1–8.
5. [5] Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 14 (2013), 933–942.
6. [6] Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
7. [7] Shojaei, F., Ferrara, N., Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 68 (2008), 5501–5504.
8. [8] Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009), 220–231.
9. [9] Gunsilius, E., Duba, H.C., Petzer, A.L., Kähler, C.M., Grünewald, K., Stockhammer, G., et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355 (2000), 1688–1691.
10. [10] Streubel, B., Chott, A., Huber, D., Exner, M., Jäger, U., Wagner, O., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351 (2004), 250–259.
11. [11] Rigolin, G.M., Fraulini, C., Ciccone, M., Mauro, E., Bugli, A.M., De Angeli, C., et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 107 (2006), 2531–2535.
12. [12] Pezzolo, A., Parodi, F., Corrias, M.V., Cinti, R., Gambini, C., Pistoia, V., Tumor origin of endothelial cells in human neuroblastoma. J. Clin. Oncol. 25 (2007), 376–383.
13. [13] Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468 (2010), 824–828.
14. [14] Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K.E., Geber, A., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468 (2010), 829–833.
15. [15] Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 4274–4280.
16. [16] Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J., Et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17 (2003), 1253–1270.
17. [17] Dontu, G., Wicha, M.S., Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J. Mammary Gland Biol. Neoplasia 10 (2005), 75–86.
18. [18] Grange, C., Bussolati, B., Bruno, S., Fonsato, V., Sapino, A., Camussi, G., Isolation and characterization of human breast tumor-derived endothelial cells. Oncol. Rep. 15 (2006), 381–386.
19. [19] Bussolati, B., Grange, C., Sapino, A., Camussi, G., Endothelial cell differentiation of human breast tumour stem/progenitor cells. J. Cell Mol. Med. 13 (2009), 309–319.
20. [20] Burcombe, R.J., Makris, A., Richman, P.I., Daley, F.M., Noble, S., Pittam, M., et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer 92 (2005), 147–155.
21. 2+ influx. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 851–858.
22. [22] Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10 (2008), 619–624.
23. [23] Olivier, M., Langerød, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12 (2006), 1157–1167.
24. [24] Varna, M., Bousquet, G., Plassa, L.F., Bertheau, P., Janin, A., TP53 status and response to treatment in breast cancers. J. Biomed. Biotechnol., 2011, 2011, 284584.
25. [25] Agelopoulos, K., Greve, B., Schmidt, H., Pospisil, H., Kurtz, S., Bartkowiak, K., et al. Selective regain of egfr gene copies in CD44+/CD24−/low breast cancer cellular model MDA-MB-468. BMC Cancer, 10, 2010, 78.
26. [26] Lv, N., Xie, X., Ge, Q., Lin, S., Wang, X., Kong, Y., et al. Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn. Pathol., 6, 2011, 118.
27. [27] Shao, M.M., Zhang, F., Meng, G., Wang, X.X., Xu, H., Yu, X.W., et al. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast. Histopathology 59 (2011), 264–273.
28. [28] Coradini, D., Fornili, M., Ambrogi, F., Boracchi, P., Biganzoli, E., TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. J. Biomed. Biotechnol., 2012, 2012, 254085.
29. [29] Kudo-Saito, C., Shirako, H., Takeuchi, T., Kawakami, Y., Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15 (2009), 195–206.
30. [30] Kurrey, N.K., Jalgaonkar, S.P., Joglekar, A.V., Ghanate, A.D., Chaskar, P.D., Doiphode, R.Y., et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27 (2009), 2059–2068.
31. [31] Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A.S., Ali, S., et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69 (2009), 2400–2407.
32. [32] Min, C.E.S., Sherr, D.H., Sonenshein, G.E., NF-nB and epithelial to mesenchymal transition of cancer. J. Cell. Biochem. 104 (2008), 733–744.
33. [33] Wellner, U.S.J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11 (2009), 1487–1495.
34. [34] Shawber, C.J., Funahashi, Y., Francisco, E., Vorontchikhina, M., Kitamura, Y., Stowell, S.A., et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J. Clin. Invest. 117 (2007), 3369–3382.
35. [35] Valtola, R., Salven, P., Heikkilä, P., Taipale, J., Joensuu, H., Rehn, M., et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 154 (1999), 1381–1390.
36. [36] Witmer, A.N., van Blijswijk, B.C., Dai, J., Hofman, P., Partanen, T.A., Vrensen, G.F., et al. VEGFR-3 in adult angiogenesis. J. Pathol. 195 (2001), 490–497.
37. [37] Alvero, A.B., Chen, R., Fu, H.H., Montagna, M., Schwartz, P.E., Rutherford, T., et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8 (2009), 158–166.
38. [38] Burcombe, R.J., Makris, A., Richman, P.I., Daley, F.M., Noble, S., Pittam, M., et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer 92 (2005), 147–155.
39. [39] Arnedos, M., Nerurkar, A., Osin, P., A'Hern, R., Smith, I.E., Dowsett, M., Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann. Oncol. 20 (2009), 1948–1952.
40. [40] Neubauer, H., Gall, C., Vogel, U., Hornung, R., Wallwiener, D., Solomayer, E., et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 28 (2008), 1797–1804.
41. [41] Hirata, T., Shimizu, C., Yonemori, K., Hirakawa, A., Kouno, T., Tamura, K., et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br. J. Cancer 101 (2009), 1529–1536.
42. [42] Tacca, O., Penault-Llorca, F., Abrial, C., Mouret-Reynier, M.A., Raoelfils, I., Durando, X., et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 12 (2007), 636–643.
43. [43] Van de Ven, S., Smit, V.T., Dekker, T.J., Nortier, J.W., Kroep, J.R., Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat. Rev. 37 (2011), 422–430.